Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(3.48)
# 813
Out of 4,959 analysts
134
Total ratings
45%
Success rate
5.61%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $10 → $8 | $3.64 | +119.78% | 7 | Aug 8, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $49.08 | +93.56% | 12 | Jul 29, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $7.55 | +231.13% | 1 | Jul 1, 2025 | |
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $4.61 | +30.15% | 2 | Jun 23, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $11.99 | +108.51% | 3 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $194.30 | +44.11% | 4 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $26.92 | +178.66% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $9.77 | +411.77% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $2.88 | +594.44% | 2 | Mar 25, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $150.49 | +42.87% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $1.87 | +167.38% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $24.30 | +723.05% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $23.31 | +7.25% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.01 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $13.50 | +122.22% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.09 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.52 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $30.92 | +191.07% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.93 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $131.88 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.33 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.51 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.31 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $71.28 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.63 | +2,296.17% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $46.35 | +14.35% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $38.84 | +67.35% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $71.52 | -16.11% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.62 | +2,986.42% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.74 | +82.48% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.60 | +587.50% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $135.43 | -4.01% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $589.48 | +28.93% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $15.10 | -0.66% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $8.19 | +571.55% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.76 | +1,604.55% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.17 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.01 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $414.68 | -39.71% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $85.04 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $42.69 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.43 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $15.49 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $15.70 | +40.13% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.91 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.58 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $210.60 | -54.89% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Aug 8, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $3.64
Upside: +119.78%
BridgeBio Pharma
Jul 29, 2025
Reiterates: Overweight
Price Target: $95
Current: $49.08
Upside: +93.56%
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $7.55
Upside: +231.13%
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $4.61
Upside: +30.15%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $11.99
Upside: +108.51%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $194.30
Upside: +44.11%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $26.92
Upside: +178.66%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $9.77
Upside: +411.77%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $2.88
Upside: +594.44%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $150.49
Upside: +42.87%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $1.87
Upside: +167.38%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $24.30
Upside: +723.05%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $23.31
Upside: +7.25%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.01
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $13.50
Upside: +122.22%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $7.09
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.52
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $30.92
Upside: +191.07%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $131.88
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.33
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.51
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.31
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $71.28
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.63
Upside: +2,296.17%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $46.35
Upside: +14.35%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $38.84
Upside: +67.35%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $71.52
Upside: -16.11%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.62
Upside: +2,986.42%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.74
Upside: +82.48%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.60
Upside: +587.50%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $135.43
Upside: -4.01%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $589.48
Upside: +28.93%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $15.10
Upside: -0.66%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $8.19
Upside: +571.55%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.76
Upside: +1,604.55%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.17
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $9.01
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $414.68
Upside: -39.71%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $85.04
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $42.69
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.43
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $15.49
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $15.70
Upside: +40.13%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $13.91
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $58.58
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $210.60
Upside: -54.89%